Global specialty pharma company dedicated to improve the health of dogs, cats and horses


Nextmune is a science driven, global specialty pharmaceutical company dedicated to improve health for dogs, cats and horses.

Nextmune was created by Fidelio through the acquisitions and mergers of seven companies in the Netherlands, Spain, Belgium, Norway and the U.S. between 2015 and 2018.

The company is #1 globally within the growing market for allergy diagnostics and treatment (more than 95% white space remaining).

Nextmune has the only licensed immunotherapy in Europe, sells its products to more than 78 countries, has over 15,000 veterinary clients and has licensed production facilities in the U.S. and Europe.

CEO: Magnus Kjellberg
Head office: Stockholm, Sweden
Employees: 100
Acquisition year: 2015
Acquisitions: 7
Industry: Specialty pharma / Animal health

Related news